PMC:7499584 / 7949-9052 JSONTXT

{"project":"2_test","denotations":[{"id":"32829416-20452219-45163168","span":{"begin":182,"end":186},"obj":"20452219"},{"id":"32829416-22020302-45163169","span":{"begin":203,"end":207},"obj":"22020302"},{"id":"32829416-22020302-45163170","span":{"begin":919,"end":923},"obj":"22020302"},{"id":"T64389","span":{"begin":182,"end":186},"obj":"20452219"},{"id":"T53252","span":{"begin":203,"end":207},"obj":"22020302"},{"id":"T55228","span":{"begin":919,"end":923},"obj":"22020302"}],"text":"Celgosivir (6-O-butanoyl castanospermine), an approved α-glucosidase inhibitor drug for type 2 diabetes and Gaucher’s disease, inhibits all four Dengue, DENV serotypes (Sayce et al. 2010; Rathore et al. 2011). “Fluorescence microscopy showed that the antiviral mechanism of Celgosivir, is in part, due to misfolding and accumulation of DENV non-structural protein 1 (NS1) in the endoplasmic reticulum” (Lachmann 2003). Moreover, Celgosivir modulates the host’s unfolded protein response (UPR) for its antiviral action. Significantly, Celgosivir is effective in lethal challenge mouse models that recapitulate primary or secondary antibody-dependent enhanced DENV infection. Celgosivir-treated mice showed enhanced survival, reduced viremia and robust immune response, as reflected by serum cytokine analysis. Importantly, survival increased even after treatment was delayed till 2 days post-infection.” (Rathore et al. 2011). Together, this suggests that Celgosivir, which has been clinically determined to be safe in humans, may be a valuable candidate for clinical testing in COVID19 patients. (Ibid)."}